Study guide

5.6 Human-Subjects Research Standards & Patient Access to Information

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

5.6 Human-Subjects Research Standards & Patient Access to Information

Key Takeaways Explain This Topic AI

The Common Rule and IRB review govern human-subjects research; clinical care testing follows clinical consent/quality pathways and is not automatically “research.”

Distinguish research participation (protocol, IRB, study consent) from clinical genetic testing ordered for diagnosis/management—even when a lab also has a research repository.

Patients generally have rights to access their medical records and results under HIPAA access provisions, with limited exceptions and institutional processes.

The right not to know—declining results or certain secondary findings—is a recognized autonomy interest that counselors must respect and document within clinical/policy limits.

Board vignettes often test whether the next step is IRB/research consent, clinical consent, facilitating record access, or honoring a preference not to receive information.

Last updated: August 2026

Research standards and access rights in Domain 5C

The final Domain 5C cluster ties human-subjects research standards to patient access to information . Genetic counselors work at the seam of clinical testing, biobanking, return of results, and client autonomy—including the choice not to learn certain information. Boards test whether you can tell research from clinical care , when an Institutional Review Board (IRB) matters, and how to honor access and “not knowing” preferences within policy.

The Common Rule and IRB oversight

The Federal Policy for the Protection of Human Subjects (the Common Rule , including the 2018 revisions as implemented) sets baseline requirements for much federally funded or otherwise covered human-subjects research in the United States. Institutions apply IRB review to determine whether an activity is research involving human subjects, whether it is exempt, and what consent and safeguards are required.

Concept Meaning for genetics practice Exam cue

Human-subjects research Research involving living individuals via interaction/intervention or identifiable private information, per regulatory definitions Is this a study or clinical care?

IRB Committee reviewing risks, benefits, consent, privacy, and subject selection “Do we need IRB approval before recruiting?”

Informed consent (research) Study-specific consent addressing purpose, procedures, risks, benefits, alternatives, confidentiality, voluntariness, whom to contact Handing a clinical test consent and calling it research consent

Exempt / expedited / full review Pathways based on risk and design (high-level awareness) Not all chart reviews are identical

Return of research results Protocol-dependent; may differ from clinical reporting standards “Will I get my research sequencing back?”

Why counselors must care

Recruiting clinic patients into studies requires clear separation of clinical relationship and research invitation —no coercion (“you only get counseling if you enroll”).

Residual samples sent to a research repository need appropriate consent/authorization pathways.

Research results may be preliminary , lack CLIA clinical validation, or be non-returnable under the protocol—counsel accordingly.

Secondary findings policies in research may differ from clinical ACMG-style frameworks.

Research testing vs clinical testing

This distinction is a Domain 5C favorite.

Feature Clinical genetic testing Research genetic testing / study sequencing

Purpose Diagnosis, management, reproductive decisions for this patient Answer a scientific question; generalizable knowledge

Oversight Clinical consent, lab accreditation (e.g., CLIA), institutional clinical policies IRB/protocol, research consent, sponsor rules

Result use Placed in medical record for care (typical) May be summary only, delayed, partial, or not returned

Billing Insurance/self-pay clinical pathways Often study-funded; not a substitute for denied clinical care without clarity

Reanalysis duty Clinical policies/evolving standards Protocol-defined

Hybrid traps: A clinical lab may ask permission to store de-identified data for research, or a study may offer clinical confirmatory testing. Best counseling names each pathway , what will be returned, and what goes in the medical record.

Scenario cue: If the vignette says “protocol,” “IRB,” “study arm,” or “not returned to participants,” think research. If it says “ordered for diagnosis,” “CLIA lab,” “medical record,” think clinical—even if the patient hopes researchers will “also look.”

Patient access to results and records

Under the HIPAA Privacy Rule, individuals generally have a right of access to inspect and obtain copies of PHI in a designated record set, including many clinical genetic test reports and counseling notes, subject to limited exceptions (for example, certain psychotherapy notes or circumstances involving serious harm as defined in regulation/policy). Practical counseling points:

Facilitate lawful access — tell patients how to request records through health-information management/portals; do not invent barriers.

Timeliness — institutions must follow regulatory and policy timelines; counselors help navigate, not obstruct.

Interpretation vs dump — patients can access reports; counselors still offer interpretive sessions so raw data are not mistaken for clinical advice.

Third-party apps / downloads — patients may export data; discuss privacy risks without unlawfully blocking access.

Minors and proxies — access rules involve parental rights, adolescent confidentiality policies, and personal representatives—follow institutional/legal frameworks.

Access request Appropriate response Inappropriate response

Patient wants copy of variant report Explain request process; offer counseling visit “Genetics results are never releasable to patients”

Patient wants research-only sequencing file Check protocol—research data access may differ from clinical designated record set Promise clinical-grade interpretation of non-CLIA research data

Relative wants patient’s record Authorization/personal representative rules (see 5.5) Release because of shared DNA

  • Patient disputes a note Explain amendment request process Silently rewrite history without process
  • The right not to know

Autonomy includes declining information. In genetics this appears as:

Declining predictive testing entirely.

Declining secondary findings analysis when optional.

Asking not to be told a particular category of results (within what the lab/order can operationalize).

Preferring staged disclosure (e.g., learn cancer risk results first, defer neurodegenerative risk if separable).

Principle Counseling application Limit

Right not to know Respect refusal of predictive information after adequate explanation of implications Cannot always un-order a test already resulted in the chart—plan preferences before analysis when possible

Informed refusal Document what was declined and that residual risks/family implications were discussed Refusal does not erase duties to document and offer future contact

Family implications Still discuss that relatives may benefit if the patient later shares or if other pathways exist Do not coerce testing “for the family”

Clinically urgent results Some findings may be hard to silo once ordered (panel design) Choose tests that match informational preferences when feasible

Exam distractors: forcing unwanted predictive results “because knowledge is always better,” or conversely refusing to discuss that declining testing has family and medical consequences.

Integrating research, access, and not-knowing

Scenario A — clinic vs study: Parents want exome for a child’s epilepsy. A researcher offers “free research exome” with no clinical report. Best counseling: research exome may not replace CLIA clinical testing for care; if they need results for management, pursue clinical testing (with insurance/resource navigation as in Domain 5A–B). Study enrollment is voluntary and separate.

Scenario B — access: Adult patient requests download of their clinical gene panel PDF from the portal. Best action: support access through proper channels and offer an interpretive appointment—not withhold the report to force an in-person visit if policy grants electronic access.

Scenario C — not to know: Asymptomatic client wants testing only for a known familial cardiovascular variant and declines opportunistic secondary finding categories that the lab can exclude. Best action: order/consent consistent with that preference when technically available; document informed refusal of additional analysis.

Scenario D — recontact research: A past study participant is recontacted because a variant is now classified pathogenic. Best awareness: follow protocol/consent terms and institutional process for recontact; do not assume identical rules to clinical reanalysis programs.

Common traps

Treating research sequencing as equivalent to clinical diagnosis without confirmatory pathways.

Coercing study enrollment as a condition of clinical care.

Blocking patient access to clinical records contrary to HIPAA access rights.

Ignoring the right not to know or, opposite error, never explaining consequences of not knowing for medical/family decisions.

Assuming research data automatically enter the medical record—or that clinical data may be dropped into a public dataset without consent/IRB pathways.

Quick exam checklist

Is the activity clinical care or human-subjects research (IRB/protocol)?

Will results be returned , CLIA-confirmed , and charted ?

Is the patient seeking access to their own records vs a third party seeking disclosure?

Did we honor not knowing preferences within what the test design allows—and document informed refusal?

Are consent documents matched to the actual pathway (clinical vs research)?